$60,000 of GENETIX BIOTHERAPEUTICS INC. (FORMERLY BLUEBIRD BIO INC.) lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues and legislation related to access to gene therapies and treatment of rare diseases. Issues and legislation related to access to gene therapies and treatment of rare diseases."
You can find more data on corporate lobbying on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
